Carbamate compounds and of making and using same

摘要

This disclosure provides compounds having the structure:;
wherein L3, R7, Rd and p are defined herein, which are modulators of MAGL and/or ABHD6. Further provided is the use of these compounds as medicinal agents, processes for their preparation, and pharmaceutical compositions that include the disclosed compounds. The disclosure also provides a method of treating a patient in need thereof, where the patient is suffering from indications such as pain, solid tumor cancer and/or obesity comprising administering a disclosed compound or composition.

主权项

1. A compound represented by:wherein
Ra and Rb together with the nitrogen to which they are attached, form a 4-6 membered heterocyclic ring which may have an additional heteroatom selected from O, S, and N; wherein the 4-6 membered heterocyclic ring is optionally substituted by one or more substituents selected from the group consisting of halogen, cyano, oxo, C1-6alkyl, —S(O)w—C1-6alkyl (where w is 0, 1 or 2), hydroxyl, —C(O)—C1-6alkyl, —NH2, and —NH—C(O)—C1-6alkyl; L3 is C1-C6alkylene, wherein C1-C6alkylene is substituted by an additional R7; R7 is selected from the group consisting of: wherein R7 is optionally substituted by one, two, three or four moieties independently selected from Rh; Re is selected from the group consisting of H and C1-6alkyl (optionally substituted by one, two or three halogens); and Rh is selected from the group consisting of: halogen, C1-6alkyl (optionally substituted by one, two or three halogens), C1-6alkoxy (optionally substituted by one, two or three halogens), and RaRbN—;or a pharmaceutically acceptable salt or stereoisomer thereof.